Today: 11 June 2026
Nu Holdings stock jumps to $17.40 — what to watch next for Nubank shares
8 February 2026
1 min read

Nu Holdings stock jumps to $17.40 — what to watch next for Nubank shares

New York, Feb 8, 2026, 07:34 EST — The market is shut for the day.

Nu Holdings Ltd (NU) finished Friday’s session at $17.40, rising roughly 3.5%. The Brazil-based digital bank locked in gains with a late-week bounce, setting the stage before trading resumes Monday.

This is hitting Nu at a tricky moment. On one hand, U.S. equity leadership is shifting. On the other, regulators may soon let the company broaden its U.S. operations—assuming it gets past some fresh obstacles.

Interest rates are right at the center of the action. Fintech stocks can whipsaw as traders reassess where U.S. rates are headed, and next week’s packed schedule of economic data could stir things up. “Rotation is the dominant theme this year,” Angelo Kourkafas, senior global investment strategist at Edward Jones, said in a separate note. Reuters

Friday saw gains across the board. The Dow finished above 50,000 for the first time on record, lifted as investors rotated out of big tech stocks after a volatile week, Reuters noted.

Nu has its own momentum right now. On Jan. 29, the company announced it had secured conditional approval from the Office of the Comptroller of the Currency, the U.S. banking regulator, for a new national bank charter—opening the door to offering products under American regulations. CEO David Vélez called a “digital-first, customer-centric model” the way forward for global finance. Co-founder Cristina Junqueira described this as “a significant step in our journey.” The company still faces further hurdles: it needs green lights from both the Federal Deposit Insurance Corporation and the Federal Reserve, plus it must capitalize the new bank within a year and get it up and running in 18 months. Nu International

Investors now turn to whether upcoming results will justify the stock’s recent climb. Eyes are on Brazil and Mexico growth, credit costs, and just how much management reveals on U.S. expansion timing and spending.

The U.S. plan’s far from wrapped up. It’s an ongoing process, with conditional approvals dragging on—and if delays pile up, or the rules tighten, sentiment could flip fast. That risk’s sharper if markets shift defensive again.

Nu faces macro headwinds on its home turf too. Softer consumer sentiment in Brazil, currency volatility, or an unexpected spike in loan defaults—all of these could squeeze profits and bring the stock’s valuation back into question.

Nu’s next big check-in comes Feb. 25, when the company is set to report fourth-quarter results and hold its conference call, according to its investor calendar.

Stock Market Today

  • Trulieve Stock Climbs on NYSE Debut and $50 Million Buyback Plan
    June 11, 2026, 11:02 AM EDT. Trulieve Cannabis Corp transitioned its stock to the NYSE under ticker TRLV, marking a shift from OTC and Canadian exchanges. On its debut, shares closed at $11.50, down slightly by 0.43%, but rose to around $11.78 in early trading. The company approved a $50 million buyback program, allowing the repurchase and cancellation of up to 5% of its float, signaling confidence in the firm's long-term value. Recent financials showed $287 million revenue, a 59% gross margin, and $42 million free cash flow for Q1. The move to a major U.S. exchange reflects Trulieve's intent to attract steadier demand amid less restrictive legal shifts by federal agencies on marijuana scheduling.

Latest articles

Theriva Biologics Pops on VCN-01 Study Results, Gets Traders’ Attention

Theriva Biologics Pops on VCN-01 Study Results, Gets Traders’ Attention

11 June 2026
TOVX soared 74.6% to $0.4252 after Theriva Biologics published Phase 1 VCN-01 data showing survival and biomarker signals in head-and-neck cancer, but the jump was not due to drug approval or revenue; investors face ongoing financing, dilution, and clinical-trial execution risks, with the company’s cash runway only into Q1 2027 and substantial doubt about its ability to continue as a going concern without new capital.
Trulieve Stock Turns Heads on NYSE After $50 Million Buyback

Trulieve Stock Turns Heads on NYSE After $50 Million Buyback

11 June 2026
Trulieve began NYSE trading as TRLV this week after moving from OTC/CSE, authorized a buyback of up to $50 million or 8.5 million shares, and closed its first NYSE session at $11.50, down 0.43%, before trading near $11.78 early Thursday, as investors weigh whether the uplisting and buyback will boost demand amid ongoing federal cannabis policy uncertainty.
Propanc Biopharma Jumps on $5 Million Buyback Plan, Investors React

Propanc Biopharma Jumps on $5 Million Buyback Plan, Investors React

11 June 2026
Propanc Biopharma shares soared as much as 392% after authorizing up to $5 million in stock buybacks—exceeding its prior $3.1 million equity value—even as it reported just $443,702 in cash and flagged going-concern risks, with investors now focused on whether its lead cancer drug PRP will advance to a planned Phase 1b trial this year.
Windows 11 printer alert: Microsoft tightens the screws on legacy V3/V4 drivers in 2026
Previous Story

Windows 11 printer alert: Microsoft tightens the screws on legacy V3/V4 drivers in 2026

JPMorgan (JPM) stock price jumps nearly 4% as Dow tops 50,000 — what to watch before Monday’s open
Next Story

JPMorgan (JPM) stock price jumps nearly 4% as Dow tops 50,000 — what to watch before Monday’s open

Go toTop